BioSpace News Archive

Seismic Therapeutic, Inc today announced that the company will participate in four upcoming scientific conferences, presenting the company’s emerging pipeline of novel therapeutics to treat rare and prevalent autoimmune diseases.

Bayer and Google Cloud announced a collaboration on the development of artificial intelligence solutions to support radiologists and ultimately better serve patients.

Lisata Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Orphan Drug Designation (“ODD”) to LSTA1.

Allogene Therapeutics, Inc. today announced that it will participate in four investor conferences in the second quarter of 2024.

Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) today announced the successful completion of an animal study evaluating the Company’s proprietary catheter-based sensing technology for use in the renal artery.

Lonza (SIX: LONN), a global development and manufacturing partner to the pharma, biotech and nutrition industries, and NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for amyotrophic lateral sclerosis (ALS) and other severe neurodegenerative diseases.

GE HealthCare, a leader in precision care innovation, will announce its first quarter 2024 financial results before the market opens on Tuesday, April 30, 2024.

HeartBeam, Inc. (NASDAQ: BEAT) today announced new data demonstrating that applying the company’s artificial intelligence (AI) algorithms to vectorcardiography (VCG) showed considerably improved performance in the detection of atrial flutter over single-lead electrocardiograms (ECGs) and similar performance to 12-lead ECGs, the standard for diagnosing atrial flutter.

Scilex Holding Company announced launching of co-pay programs for both ZTlido® and ELYXYB® with the out-of-pocket costs for its product portfolio for commercially insured patients capped at $25 monthly, with certain eligible patients paying as low as $0.

Signati™ Medical, a medical device company dedicated to advancing men’s health, today announced the successful enrollment of the first patient in its Investigational Device Exemption (IDE) trial for the Signati Separo™, a revolutionary new device designed to streamline the vasectomy procedure.